Aller au contenu principal
Profil bibliographique

Suhasini Iyer

Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.

75Publications signalées
3057Citations signalées
1Affiliations récentes

Les institutions déclarées

Les domaines associés

Monoclonal and Polyclonal Antibodies ResearchHeme Oxygenase-1 and Carbon MonoxideCAR-T cell therapy researchGlycosylation and Glycoproteins ResearchBiosimilars and Bioanalytical Methods

Les publications récentes

Accès ouvert 2025 conference-abstract OpenAlex

820 Discovery of a novel CD123 x gamma delta T cell engager for the treatment of acute myeloid leukemia

Kevin H. Dang, Zahra Bahrami-Dizicheh, Harish Medlari, James Allison et autres

Background Gamma delta (γδ) T cells are a distinct subset of T cells with features of both innate and adaptive immunity. Based on their TCR δ chain usage, γδT cells can be divided into Vδ1 cells present in tissues, Vδ2 cells predominately …

us (code pays fourni par la source)

0 citations Regular and Young Investigator Award Abstracts
Accès ouvert 2025 article OpenAlex

Inhibition of CD38 enzyme activity on engrafted human immune cells enhances NAD+ metabolism and inhibits inflammation in an in-vivo model of xeno-GvHD

Ghenima Ahmil-Boiteau, Pranjali Dalvi, Kevin H. Dang, Harshad S. Ugamraj et autres

Introduction: CD38 is highly expressed on immune cells. It catabolizes NAD+, which is a critical cofactor for enzymes involved in metabolism and energy production. Methods and results: We developed TNB-738, a fully human antibody that potently inhibits human CD38 enzymatic activity on …

fr, us (code pays fourni par la source)

1 citation Frontiers in Immunology
Accès ouvert 2023 article OpenAlex

Evaluating DFHBI-Responsive RNA Light-Up Aptamers as Fluorescent Reporters for Gene Expression

Alicia Climent-Catala, Iván Casas‐Rodrigo, Suhasini Iyer, Rodrigo Ledesma‐Amaro et autres

High Resolution Image Download MS PowerPoint Slide Protein-based fluorescent reporters have been widely used to characterize and localize biological processes in living cells. However, these reporters may have certain drawbacks for some applications, such as transcription-based studies or biological interactions with fast …

gb, ch (code pays fourni par la source)

7 citations ACS Synthetic Biology
Accès ouvert 2022 article OpenAlex

A T-cell engaging bispecific antibody with a tumor-selective bivalent folate receptor alpha binding arm for the treatment of ovarian cancer

Brian C. Avanzino, Kirthana Prabhakar, Pranjali Dalvi, Sharon Hartstein et autres

The use of T-cell engagers (TCEs) to treat solid tumors is challenging, and several have been limited by narrow therapeutic windows due to substantial on-target, off-tumor toxicities due to the expression of low levels of target antigens on healthy tissues. Here, we …

us (code pays fourni par la source)

19 citations OncoImmunology
Accès ouvert 2022 article OpenAlex

TNB-738, a biparatopic antibody, boosts intracellular NAD+ by inhibiting CD38 ecto-enzyme activity

Harshad S. Ugamraj, Kevin H. Dang, Laure‐Hélène Ouisse, Benjamin Buelow et autres

Cluster of differentiation 38 (CD38) is an ecto-enzyme expressed primarily on immune cells that metabolizes nicotinamide adenine dinucleotide (NAD+) to adenosine diphosphate ribose or cyclic ADP-ribose and nicotinamide. Other substrates of CD38 include nicotinamide adenine dinucleotide phosphate and nicotinamide mononucleotide, a critical …

fr, us, in (code pays fourni par la source)

28 citations mAbs
2022 conference-abstract OpenAlex

Abstract 6244: A T cell engaging bispecific antibody utilizing a bivalent tumor-selective folate receptor alpha binding arm for the treatment of ovarian cancer

Brian C. Avanzino, Kirthana Prabhakar, Pranjali Dalvi, Sharon Hartstein et autres

Abstract The use of T cell engagers (TCEs) to treat solid tumors in humans is challenging, and several have been limited by narrow therapeutic windows due to substantial toxicity. Dose-limiting toxicities of TCEs include cytokine release syndrome (CRS) and on-target, off-tumor toxicities …

us (code pays fourni par la source)

0 citations Cancer Research
Accès ouvert 2021 article OpenAlex

Attenuating CD3 affinity in a PSMAxCD3 bispecific antibody enables killing of prostate tumor cells with reduced cytokine release

Kevin H. Dang, Giulia Castello, Starlynn Clarke, Yuping Li et autres

Background Therapeutic options currently available for metastatic castration-resistant prostate cancer (mCRPC) do not extend median overall survival >6 months. Therefore, the development of novel and effective therapies for mCRPC represents an urgent medical need. T cell engagers (TCEs) have emerged as a …

us (code pays fourni par la source)

79 citations Journal for ImmunoTherapy of Cancer
2021 conference-abstract OpenAlex

TNB585.001: A multicenter, phase 1, open-label, dose-escalation and expansion study of tnb-585, a bispecific T-cell engager targeting PSMA in subjects with metastatic castrate resistant prostate cancer.

Ben D. Buelow, Pranjali Dalvi, Kevin H. Dang, Ashwin P. Patel et autres

TPS5092 Background: Prostate cancer (CaP) is the most common cancer in US men. Disseminated CaP invariably progresses to metastatic castrate-resistant prostate cancer (mCRPC). Current treatment options for mCRPC usually lead to therapeutic resistance, and novel therapies are urgently needed. PSMA is a …

us (code pays fourni par la source)

9 citations Journal of Clinical Oncology
Accès ouvert 2021 article OpenAlex

A bispecific antibody agonist of the IL-2 heterodimeric receptor preferentially promotes in vivo expansion of CD8 and NK cells

Katherine E. Harris, Kyle J. Lorentsen, Harbani K. Malik-Chaudhry, Kaitlyn Loughlin et autres

The use of recombinant interleukin-2 (IL-2) as a therapeutic protein has been limited by significant toxicities despite its demonstrated ability to induce durable tumor-regression in cancer patients. The adverse events and limited efficacy of IL-2 treatment are due to the preferential binding …

fr (code pays fourni par la source)

43 citations Scientific Reports
Accès ouvert 2021 article OpenAlex

TNB-486 induces potent tumor cell cytotoxicity coupled with low cytokine release in preclinical models of B-NHL

Harbani K. Malik-Chaudhry, Kirthana Prabhakar, Harshad S. Ugamraj, Andrew A. Boudreau et autres

The therapeutic potential of targeting CD19 in B cell malignancies has garnered attention in the past decade, resulting in the introduction of novel immunotherapy agents. Encouraging clinical data have been reported for T cell-based targeting agents, such as anti-CD19/CD3 bispecific T-cell engager …

us (code pays fourni par la source)

40 citations mAbs
2020 conference-abstract OpenAlex

A CD3 x FRα T-cell engaging bispecific antibody for efficient killing of ovarian cancer cells with minimal cytokine release.

Ben D. Buelow, Brian C. Avanzino, Aarti Balasubramani, Andrew A. Boudreau et autres

e18050 Background: Ovarian Cancer (OvCa) is the leading cause of gynecologic cancer mortality in women. Since the introduction of platinum-based chemotherapy there has been little change in the prognosis of OvCa patients, with < 30% overall survival in advanced disease, creating an …

us (code pays fourni par la source)

1 citation Journal of Clinical Oncology
2020 conference-abstract OpenAlex

Effect of modulation of CD3 binding in a PSMAxCD3 T-cell engaging bispecific antibody on maintenance of efficient tumor cell kill and cytokine release.

Ben D. Buelow, Kevin H. Dang, Pranjali Dalvi, Yuping Li et autres

e17583 Background: Castration resistant prostate cancer (CRPC) is an incurable disease and represents a significant unmet need. Prostate specific membrane antigen (PSMA) is a protein highly expressed on the surface of prostate cancer cells; expression has been shown to increase with disease …

us (code pays fourni par la source)

1 citation Journal of Clinical Oncology

BNTIC News n’est pas le producteur de ces données. Les publications sont interrogées à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, AfricArXiv, ROR et la Banque mondiale, sans clé d’accès. OpenAlex reste optionnel. Aucun service payant n’est nécessaire et aucune donnée externe n’est enregistrée en base. Consulter les sources et leurs limites.